Regeneron Armed with PCSK9 Data: Regeneron and partner Sanofi were not to be left behind where positive data on PCSK9 inhibitors is concerned. The companies said that there experimental PCSK9 inhibitor, alirocumab, lowered "bad" cholesterol significantly in Japanese patients.